ALBANY

RT 200 in der Schleife ..eierflacher spread von 0,09%  

Datum Erster Hoch Tief Schluss     Stücke Volumen
13.05.13 11,22 11,72 10,90  11,52 $ 578.560 6,57 M
GrB  

RTK 11,59  $ ..336.849 Stücke an die Wand geschmissen ..peak 11,86  

Wartestücke 333 ..spread 3,89% ..DAX Tafel zeigt 8.339 Zählers ..Pott  +337,92%

...........and good luck  

to Present at the UBS Global Healthcare Conference14:05 15.05.13


PR Newswire

ALBANY, New York, May 15, 2013

ALBANY, New York, May 15, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that Michael M. Nolan, Vice President, Chief Financial Officer and Treasurer at AMRI, will present at the UBS Global Healthcare Conference on Wednesday, May 22, 2013 at 9:00 a.m. ET.

(Logo:  http://photos.prnewswire.com/prnh/20120229/NY61160LOGO)

An audio webcast of the corporate presentation will be available to investors and interested parties by accessing the company's website at www.amriglobal.com. This audio webcast will be archived for 90 days following the live presentation.

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).


Quelle: PR Newswire  

Datum Erster Hoch Tief Schluss     Stücke Volumen
17.05.13 11,06 11,32 10,95  11,08 $ 857.349 9,09 M
__________________________________________

..Geld on mass  

Preis 8,777 € ..342 Stücke warten auf eine Verbriefung ..spread akzeptable 3,89%  

ask Preis 11,16 $ Schleife 5.400 spread 0,09% ..Sohn:: soweit Dein Auge reicht alles fruchtbares Ackerland ..und es wird alles mal Dein  

guter Preis 8,781 € gute Stücke 342 gute 8.358 DAX Zählerpunkte  

79.853 Stücke sind gedonnert  

at the Jefferies 2013 Global Healthcare Conference14:05 30.05.13


PR Newswire

ALBANY, New York, May 30, 2013

ALBANY, New York, May 30, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that Thomas E. D'Ambra, Ph.D., Chairman, President and Chief Executive Officer at AMRI, will present at the Jefferies 2013 Global Healthcare Conference on Thursday, June 6, 2013 at 11:30 a.m. ET.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )

An audio webcast of the corporate presentation will be available to investors and interested parties by accessing the company's website at www.amriglobal.com. This audio webcast will be archived for 90 days following the live presentation.

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).


Quelle: PR Newswire  

Datum Erster Hoch Tief Schluss     Stücke Volumen
03.06.13 10,98 10,98 10,05  10,40 $ 531.606 4,89 M
GrB  

as Chairman of the Board of Directors22:35 05.06.13


PR Newswire

ALBANY, New York, June 5, 2013

ALBANY, New York, June 5, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI), a leading global contract research and manufacturing organization, has announced that the Board of Directors has unanimously voted to separate the role of Chairman and Chief Executive Officer and has named William S. Marth, an active member of the AMRI Board of Directors, as Chairman of the Board, effective June 5, 2013. The position of Chairman has been held by Thomas E. D'Ambra, Ph.D. since the Company's founding.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )

Dr. D'Ambra retains his roles as a member of the Board of Directors, President and CEO. Mr. Marth was appointed to the AMRI Board of Directors in 2012, joining Veronica G. H. Jordan, Ph.D.; Gabriel Leung; Kevin O'Connor; Arthur J. Roth; and Una S. Ryan, O.B.E., Ph.D.

Mr. Marth said, "AMRI maintains a unique and strong position providing a broad range of drug discovery, development and manufacturing services to the pharmaceutical, biotechnology and related industries. I have been impressed with the Company's accomplishments and potential and look forward to contributing to growing both the depth and breadth of AMRI's services in my role as Chairman."

Dr. D'Ambra said, "Bill is an accomplished and visionary industry leader who has an unparalleled record of commercial success. Since joining the Board approximately one year ago, he has been very helpful to me personally as well as to the Company. I am confident with Bill as our Chairman, that the Company is poised for continued and greater success. I, along with the rest of the members of the Board of Directors, look forward to continuing to serve with Bill on behalf of all AMRI shareholders. AMRI's success has been built on a reputation for the highest quality standards in its work and ethics. Our corporate governance structure demonstrates AMRI's commitment to sustaining a superior level of performance."

Mr. Marth, formerly President and Chief Executive Officer of Teva – Americas, retired from Teva in 2012. He had previously served as President and Chief Executive Officer of Teva North America from January 2008 to June 2010 and prior to that as President and Chief Executive Officer of Teva USA. He was previously Executive Vice President and Vice President of Sales and Marketing for Teva USA.

Mr. Marth played a significant role in establishing Teva as a leading Specialty Pharmaceutical company and being ultimately recognized as the worldwide No. 1 producer of generic drugs. In his role, he led respiratory, neuroscience, oncology and women's healthcare divisions, as well as Latin America and Canada. He was a member of Teva's global executive management team and Teva Americas' board of directors since 2007. He brings to this role his global experience in Strategic Planning, IR, R&D, Supply Chain and Regulatory. He was the architect of the $6.8 billion Cephalon and $7.4 billion Barr Laboratories acquisitions. Prior to joining Teva USA, he held various positions with the Apothecon division of Bristol-Myers Squibb.

Mr. Marth, who earned his B.Sc. in Pharmacy from the University of Illinois in 1977 and his M.B.A. in 1989 from the Keller Graduate School of Management, DeVry University, is a licensed pharmacist and serves on various other boards and committees, including The University of the Sciences in Philadelphia and the Board of Ambassadors for John Hopkins' Project RESTORE. In addition, Mr. Marth served as the Chairman of the Board of the Generic Pharmaceutical Association (GPhA) in 2008 and 2009 and the American Society for Health-System Pharmacists (ASHP) in 2010.

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).


Quelle: PR Newswire  

at the 2013 Wells Fargo Securities Healthcare Conference14:05 12.06.13


PR Newswire

ALBANY, N.Y., June 12, 2013

ALBANY, N.Y., June 12, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that Thomas E. D'Ambra, Ph.D., President and Chief Executive Officer at AMRI, will present at the 2013 Wells Fargo Securities Healthcare Conference on Wednesday, June 19, 2013 at 10:40 a.m. ET.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

SOURCE AMRI


Quelle: PR Newswire  

, Business Development14:05 17.06.13


PR Newswire

ALBANY, New York, June 17, 2013

ALBANY, New York, June 17, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that Susan Collins has been promoted to Director of Business Development for North American Discovery Services, reporting to Christopher Conway, Vice President, Business Development. In this new role, Ms. Collins is responsible for leading AMRI's North American Discovery Business Development team in the promotion of the full spectrum of AMRI's global drug discovery services. Bringing 19 years of pharmaceutical industry and leadership experience to this role, Ms. Collins will manage AMRI's North American discovery business development activities and professionals and spearhead AMRI's efforts to expand discovery opportunities and business within the sector.

(Logo:  http://photos.prnewswire.com/prnh/20120229/NY61160LOGO)

Mr. Conway said, "Susan is a top-performing sales professional with a proven ability to drive territorial revenue growth and increase market penetration through exceptional customer relationship skills. Her track record since joining AMRI and prior leadership experience position her well to be very successful in this expanded role. I would like to take this opportunity to publicly congratulate Susan and wish her well in this new position. I look forward to working with her more closely going forward."

Before joining AMRI's discovery team in 2012, Ms. Collins held roles of increasing responsibility in sales and leadership positions at Organon BioSciences, which was later acquired by Schering-Plough and Merck. As Region Sales Director, she was responsible for leading award-winning management and representative teams in the promotion of CNS, cardiovascular, anti-infective, anesthesia, pain management and contraceptive products to the medical community across 28 states. Directing teams of up to 125 employees, Ms. Collins was responsible for generating sales of more than $174 million with a $7.8 million operating budget.  

Thomas E. D'Ambra, Ph.D., President and CEO, AMRI, said, "AMRI's business development professionals are integral in creating and building long-term relationships and partnerships with our many customers. AMRI's discovery services are complex, cover our global locations and require customization of offerings and solutions for our customers' specific needs. Susan has demonstrated an innovative and ambitious approach to building business and customer relationships since joining AMRI in 2012. We look forward to working with Susan and her team in building our North American discovery business to the next level of success."

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).


Quelle: PR Newswire  

to Handle Controlled Substances14:05 18.06.13


PR Newswire

ALBANY, New York, June 18, 2013

-- Approval to Handle Schedule 2 and 2N Controlled Substances at this location Further Supports

-- AMRI SMARTSOURCING™ Offering

ALBANY, New York, June 18, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that its Burlington, Mass., site has received approval to expand its current U.S. Drug Enforcement Administration (DEA) registration to handle Schedule 2 and 2N controlled substances. The license represents the DEA's acknowledgement of Burlington's physical security and quality systems, including inventory control and documentation.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO)

With its cGMP aseptic formulation and filling expertise, AMRI Burlington supports pre-clinical through commercial scale production of liquid-filled and lyophilized parenterals. The addition of Schedule 2 compounds to this registration allows Burlington to perform controlled substance work for its customers, both in the laboratory and on the engineering/production side.

Steven R. Hagen, Ph.D., Senior Vice President of Pharmaceutical Development and Manufacturing at AMRI, said, "As part of its fully integrated global contract services offering, AMRI has the expertise to support cGMP production for a wide spectrum of products across platform technologies, both at the small and large scale. The DEA's recognition of the security and documentation systems at the Burlington facility is just another example of how AMRI's formulation and filling capabilities can meet the various needs of the pharmaceutical and biotechnology industries."

Dr. Hagen continued, "Receiving approval from the DEA to handle controlled substances demonstrates AMRI's continued ability to offer compliant, quality manufacturing process options to our customers. Our expanded license allows us to continue to build on AMRI SMARTSOURCING™ in the area of manufacturing."

In DEA terms, Burlington is considered a dosage form manufacturer that can package/label and repackage/relabel. This expanded registration will allow Burlington to offer filling services for Schedule 2, 2N, 3, 3N, 4, and 5 controlled substances, as well as offer these services to complement more of the projects handled by AMRI's Rensselaer site. AMRI's Rensselaer site – which provides contract cGMP manufacturing of bulk active pharmaceuticals and advanced intermediates – holds a DEA controlled substance license permitting the manufacture of Schedule 1 through 5 controlled substances.

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).


Quelle: PR Newswire  

Frankfurt 8,782 € Nasdaq 11,80 $  
buran und tau  

Buchsatz 25-06

Datum Erster Hoch Tief Schluss     Stücke Volumen
25.06.13 11,56 11,70 11,09  11,23 $ 191.149 1,66 M

GrB  

Kaufpreis 12,60 $ Schleife 200 spread 4,56% buran und tau  

Frankfurt, 02.07.13 ,GrB  

12,76 $ +0,63% +0,08 $ , 03.07.13 , Pott +394,57% , GrB  

http://www.ariva.de/news/...on-of-AMRI-Burlington-MA-Facility-4611375 GrB  

14:05 23.07.13


PR Newswire

ALBANY, N.Y., July 23, 2013

ALBANY, N.Y., July 23, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced it will issue second quarter financial results before the opening of the market on Tuesday, August 6, 2013.  Following the release of its results, the company will host a conference call and simultaneous audio webcast at 10 a.m. ET.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )

The conference call can be accessed by dialing 888-417-8533 (domestic calls) or 719-325-2429 (international calls) at 9:50 a.m. ET and entering passcode 8730056.  The audio webcast will be available live via the Internet and can be accessed on the company's website at www.amriglobal.com.  Replays of the audio webcast can also be accessed for up to 90 days after the call via the investor area of the company's website at www.amriglobal.com/investor_relations/.

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

SOURCE AMRI


Quelle: PR Newswire  

RTK 12,37 $ SKP 2,66% EK 12,05 $ 178.430 Stücke sind getickert ..max Leuchte 12,47

vegetarisch ernähren und zweimal Nachschlag ..wenn ich sowas höre dann den Nachschlag mit nem deftigen Kuharsch ..so gestern beim Grillen ..manche Typen ticken nich mehr ganz tacko

buran,Der BÖRSEN GRILLMEISTER  

es wird Tag und ich fahre heim ..da sitzt die kleine Süsse vor mir ..und ich denke sofort ..das kann doch nur meine kleine ALBANY sein

Datum Erster Hoch Tief Schluss     Stücke Volumen
08.08.13 11,99 12,24 11,964  12,15 $ 199.680 2,40 M

wir fuhren gemeinsam nach ihr heim ..und tranken dann vom Russischen süssen Wein

Albany & buran